A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Recruiting

Diroximel FumarateA Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Sponsor:

Biogen

Code:

NCT05688436

Conditions

Multiple Sclerosis

Eligibility Criteria

Sex: Female

Age: 18 - 49

Healthy Volunteers: Not accepted

Interventions

Diroximel Fumarate

Alemtuzumab

Fingolimod

Glatiramer acetate

Interferon beta

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-08. This information was provided to ClinicalTrials.gov by Biogen on 2025-10-20.